Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 83006 refers to a laboratory test that measures the growth stimulation expressed gene 2, commonly known as ST2, which is a member of the interleukin 1 receptor family. This biomarker exists in two distinct forms: soluble ST2 (sST2) and transmembrane-bound ST2-ligand (ST2L). The presence and levels of ST2 in the body can provide critical insights into a patient's cardiac health. Specifically, when utilized alongside clinical evidence, the measurement of ST2 can assist healthcare professionals in predicting adverse outcomes and mortality in patients who have experienced documented cardiac injury or stress. Furthermore, ST2 serves as a prognostic marker for potential future cardiac diseases within the general population. In response to cardiac injury or stress, healthy cardiac tissue produces sST2, which subsequently binds to interleukin-33 (IL-33). This binding action diminishes the protective effects of the ST2L receptor, which is crucial for safeguarding against myocardial fibrosis and heart failure. The testing of serum or plasma samples for ST2 levels is conducted using the enzyme-linked immunosorbent assay (ELISA) method, a widely recognized laboratory technique that allows for the accurate quantification of this biomarker.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The laboratory test associated with CPT® Code 83006 is indicated for the following conditions:

  • Cardiac Injury or Stress This test is performed to assess patients who have experienced documented cardiac injury or stress, providing valuable information regarding their prognosis.
  • Adverse Outcomes Prediction The measurement of ST2 levels can help predict adverse outcomes and mortality in patients with existing cardiac conditions.
  • Prognostic Marker for Cardiac Disease ST2 may also be utilized as a prognostic marker for future cardiac disease in the general population, aiding in early identification and management of at-risk individuals.

2. Procedure

The procedure for testing ST2 levels involves several key steps that ensure accurate measurement and analysis of the biomarker:

  • Sample Collection A blood sample is collected from the patient, typically through venipuncture. This sample will be used to isolate serum or plasma for testing.
  • Sample Preparation The collected blood sample is processed to separate the serum or plasma from the cellular components. This is crucial as the biomarker ST2 is present in the serum/plasma and not in the cellular fraction.
  • Enzyme-Linked Immunosorbent Assay (ELISA) The prepared serum or plasma is then subjected to the enzyme-linked immunosorbent assay (ELISA). This laboratory technique involves the use of specific antibodies that bind to ST2, allowing for its quantification based on the intensity of the resulting color change, which is proportional to the concentration of ST2 in the sample.
  • Result Interpretation After the ELISA procedure, the results are analyzed and interpreted by laboratory professionals. The levels of ST2 are reported, providing critical information regarding the patient's cardiac health and potential risks.

3. Post-Procedure

Post-procedure care for patients undergoing the ST2 test is generally minimal, as the test involves a standard blood draw. Patients may experience slight discomfort or bruising at the puncture site, which typically resolves quickly. There are no specific restrictions or follow-up procedures required after the test, and patients can resume their normal activities immediately. However, it is essential for healthcare providers to discuss the results with patients once they are available, as this will guide further management and treatment decisions based on the ST2 levels and the clinical context.

Short Descr GROWTH STIMULATION GENE 2
Medium Descr GROWTH STIMULATION EXPRESSED GENE 2
Long Descr Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Date
Action
Notes
2015-01-01 Added Added
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"